Core Insights - Pulmonx Corporation reported a transition period in its performance but sees significant opportunities to regain momentum through a focused operating plan aimed at commercial growth and clinical advancements [3] Financial Performance Fourth Quarter 2025 - Total worldwide revenue was $22.6 million, a 5% decrease from $23.8 million in Q4 2024, and a 7% decrease on a constant currency basis [4] - U.S. revenue decreased by 11% to $14.1 million, while international revenue increased by 8% to $8.5 million [4] - Gross profit was $17.5 million with a gross margin of 78%, up from 74% in Q4 2024 [5] - Operating expenses decreased by 11% to $27.4 million [5] - Net loss was $10.4 million, or $0.25 per share, an improvement from a net loss of $13.2 million, or $0.33 per share, in Q4 2024 [6] Full Year 2025 - Total worldwide revenue for 2025 was $90.5 million, an 8% increase from $83.8 million in 2024, and a 7% increase on a constant currency basis [7] - U.S. revenue increased by 1% to $57.0 million, while international revenue surged by 23% to $33.5 million [7] - Gross profit for the year was $67.1 million, an 8% increase compared to $62.0 million in 2024 [8] - Operating expenses rose slightly by 1% to $120.8 million [8] - Net loss for the year was $54.0 million, or $1.33 per share, an improvement from a net loss of $56.4 million, or $1.44 per share, in 2024 [9] Future Guidance - Pulmonx expects revenue for the full year 2026 to be in the range of $90 million to $92 million [10] - The company anticipates a gross margin of approximately 75% for 2026 [12] - Total operating expenses for 2026 are expected to be between $113 million and $115 million, including about $21 million in non-cash stock-based compensation [12] - Cash, cash equivalents, and marketable securities are projected to decrease by approximately $23 million for 2026 [12] Strategic Initiatives - The company has refinanced existing debt, securing up to $60 million in committed capital under a new 5-year interest-only credit facility [11] - A cost restructuring initiative has been executed to reduce operating expenses while maintaining key investments in commercial and clinical growth [11]

Core Viewpoint - Pulmonx Corporation has successfully closed a five-year credit facility of up to $60 million with Perceptive Advisors, aimed at strengthening its capital structure and extending debt maturity to 2031 [1][2][3] Financing Details - The credit facility includes an initial $40 million term loan drawn at closing to refinance existing debt, with an option for an additional $20 million available until the end of 2027, contingent on achieving specific revenue milestones [2] - The facility is interest-only until maturity in 2031, with an interest rate set at one-month Term SOFR plus 7.0%, subject to a 3.75% floor, and allows for 2.0% of the interest to be paid-in-kind for three years [2] Strategic Implications - The new debt facility is expected to enhance the company's capital structure, allowing it to focus on executing its commercial strategy and advancing key clinical programs for its life-changing treatments for severe emphysema [3] - The Pulmonx Zephyr Valve is highlighted as a leading product with strong clinical evidence and broad reimbursement, addressing significant unmet needs for patients with severe emphysema [3] Company Overview - Pulmonx Corporation is a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), with products like the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System designed for patients with severe emphysema [5] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard treatment option for improving quality of life in severe emphysema patients [5] Partner Overview - Perceptive Advisors, founded in 1999, manages approximately $8 billion and focuses on supporting advancements in the life sciences by directing financial resources to promising healthcare technologies [7]

Core Viewpoint - Pulmonx Corporation is set to release its financial results for Q4 and the full year of 2025 on March 4, 2026, with a conference call scheduled to discuss these results [1]. Company Overview - Pulmonx Corporation (Nasdaq: LUNG) is recognized as a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3]. - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are aimed at treating patients with severe emphysema/COPD [3]. - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, being included in global treatment guidelines as a standard care option for improving patient outcomes [3].

Core Insights - Pulmonx Corporation reported a total worldwide revenue of $21.5 million for Q3 2025, reflecting a 5% increase from $20.4 million in Q3 2024, and a 4% increase on a constant currency basis [4][9] - The company aims to leverage its operational foundation to expand Zephyr Valve treatment volumes while maintaining a commitment to sustainable, profitable growth [3][4] Financial Performance - U.S. revenue for Q3 2025 was $14.0 million, a 1% increase year-over-year, while international revenue reached $7.5 million, marking a 15% increase compared to Q3 2024 [4][9] - Gross profit for Q3 2025 was $16.1 million, with a gross margin of 75%, up from 74% in the same period last year [5][9] - Operating expenses increased by 4% to $30.4 million, driven by higher clinical, development, and commercial investments [5][9] - The net loss for Q3 2025 was $14.0 million, or $0.34 per share, slightly improved from a net loss of $14.1 million, or $0.36 per share, in Q3 2024 [6][9] 2025 Financial Outlook - Pulmonx updated its 2025 financial outlook, expecting total revenue to be in the range of $89 million to $90 million, with a gross margin of approximately 73% [7][9] - Total operating expenses for the full year 2025 are projected to be between $125 million and $126 million, including about $21 million in non-cash stock-based compensation [7][9] Leadership Changes - Glen French was reappointed as President and CEO, and Derrick Sung was appointed as COO and CFO [9]

Leadership Changes - Glen French has been reappointed as President and Chief Executive Officer of Pulmonx Corporation, effective immediately [1][3] - Derrick Sung has been appointed as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025 [1][3] - Steve Williamson and Mehul Joshi have resigned from their roles but will serve in advisory capacities until December 1, 2025 [1][3] Financial Performance - Preliminary revenue for the third quarter of 2025 is anticipated to be approximately $21.5 million [4] - The company plans to provide further details on its third quarter results during a conference call rescheduled for November 12, 2025 [4][6] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [9] - The company's Zephyr Endobronchial Valve is a standard treatment option for patients with severe emphysema and is commercially available in over 25 countries [9]

Core Insights - Pulmonx Corporation will release its financial results for Q3 2025 on October 29, 2025, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, aimed at treating patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized in global treatment guidelines as a standard care option for improving patient outcomes [3]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving patient outcomes [2] Upcoming Investor Conferences - Pulmonx management will present at the Wells Fargo Healthcare Conference on September 4 at 1:30 pm PT/4:30 pm ET in Boston, MA, featuring a fireside chat and 1x1 meetings [1] - The company will also participate in the Lake Street Best Ideas Growth (BIG9) Conference on September 11 in New York, NY, focusing on 1x1 meetings [1] - A live and archived webcast of the fireside chat will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTrax™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Core Insights - Pulmonx Corporation reported a strong start to 2025, emphasizing its strategy to expand patient access to Zephyr Valves and highlighting solid commercial performance [3][4]. Financial Performance - Total worldwide revenue for Q1 2025 was $22.5 million, a 20% increase from $18.9 million in Q1 2024, and a 21% increase on a constant currency basis [4][9]. - U.S. revenue reached $14.2 million, reflecting an 11% year-over-year increase, while international revenue was $8.3 million, marking a 39% increase compared to Q1 2024, and a 43% increase on a constant currency basis [4][9]. - Gross profit for Q1 2025 was $16.3 million, with a gross margin of 73%, down from 75% in the same period of 2024 [5][9]. - Operating expenses increased to $30.9 million, up 8% from $28.6 million in Q1 2024, primarily due to higher commercial investments [5][9]. - The net loss for Q1 2025 was $14.4 million, or $0.36 per share, compared to a net loss of $13.7 million, also $0.36 per share, in Q1 2024 [6][9]. 2025 Financial Outlook - The company reaffirmed its full-year 2025 revenue guidance, expecting it to be in the range of $96 million to $98 million, with a gross margin of approximately 74% [7][8]. - Total operating expenses for 2025 are anticipated to be between $133 million and $135 million, including about $22 million in non-cash stock-based compensation [7][8]. Recent Developments - Pulmonx amended its loan agreement with CIBC Innovation Banking to extend the interest-only period through October 2027 [9]. - The U.S. Department of Justice declined to intervene in a case against Pulmonx, concluding the civil investigative demand [9].